home / stock / xphy:cc / xphy:cc news

XPHY:CC News and Press, Xphyto Therapeutics Corp. - Common Shares From 06/27/22

Stock Information
Company Name: Xphyto Therapeutics Corp. - Common Shares
Stock Symbol: XPHY:CC
Market: CNQC
Menu
XPHY:CC XPHY:CC Quote XPHY:CC Short XPHY:CC News XPHY:CC Articles XPHY:CC Message Board
Get XPHY:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
XPHY:CC - Prof. Dr. Raimar Loebenberg Receives Leadership Award from the Canadian Society for Pharmaceutical Sciences

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / June 27, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) ("XPhyto" or the "Company") is pleased to congratulate Prof. Dr. Raimar Loebenberg as the 2022 recipient of the CSPS Award of Leadership in Canadian Pharmaceutic...
XPHY:CC - InvestorNewsBreaks - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Expands European Team to Add Pharmaceutical Manufacturing Expert

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that Dr. Florian A. Sahr has joined its European operations as head of project management. A German-born and internationally trained leader in formulation, technology transfer and new-product manufacturing, Dr. Sahr ...

XPHY:CC - XPhyto Adds Pharmaceutical Manufacturing Expert Dr. Florian A. Sahr to Its European Team

VANCOUVER, BC and UTTENWEILER / ACCESSWIRE / June 8, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to report that Dr. Florian A. Sahr has joined its European operations as Head of Project Management. Dr. Sahr is a German-born and...

XPHY:CC - InvestorNewsBreaks - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Reports Positive Results of Rotigotine Transdermal Patch Study

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator at the leading-edge of the life science industry, has released an update on its Rotigotine transdermal ("TDS") patch. The patch is based on the TDS platform technology developed by the company’s...
XPHY:CC - XPhyto Reports Product Developments on Platform-Based Rotigotine Transdermal Patch for Parkinson's Disease

VANCOUVER, BC, AND UTTENWEILER, GERMANY / ACCESSWIRE / May 9, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a product development report on its Rotigotine transdermal ("TDS") patch, including results of its recent human ...

XPHY:CC - InvestorNewsBreaks - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Provides Update on Market, Product Development of Key Biosensor

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released a market and product development report. The report focused on XPhyto’s sublingual oral dissolvable film ("ODF") biosensor developm...

XPHY:CC - XPhyto, Biosensors Market and Product Developments on Platform-Based Oral Dissolvable Biosensors for Oral Health and Infectious Disease

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / April 11, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a market and product development report on its Sublingual oral dissolvable film ("ODF") biosensor development ...
XPHY:CC - InvestorNewsBreaks - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Update on Rotigotine Transdermal Patch Development

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator at the leading-edge of the life science industry, is reporting on the market and product development of its Rotigotine transdermal ("TDS") patch, which is designed for the treatment of Parkinson's dise...

XPHY:CC - XPhyto Reports Market and Product Developments on Platform-based Rotigotine Transdermal Patch for Parkinson's Disease

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / April 4, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a market and product development report on its Rotigotine transdermal ("TDS") patch. The Company's Rotigotine...

XPHY:CC - InvestorNewsBreaks - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Closes First Tranche of Private Placement

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has announced that, further to its news release of March 25, 2022, it has closed the f...
Previous 10 Next 10